FDA Approves Orzeyful (oveporexton) for Narcolepsy Type 1, Addressing Underlying Biology of the Disease

The U.S. Food and Drug Administration (FDA) has approved Orzeyful (oveporexton) for the treatment of narcolepsy type 1 in adults. This marks the first drug to directly activate the brain receptor that the body's own orexin would normally stimulate, thereby restoring the missing signal and addressing the full range of symptoms caused by the disease, rather than just masking them with stimulants or sedatives.